Johnson & Johnson (JNJ) announced promising booster data Tuesday showing 94% efficacy for its COVID-19 vaccine when given after six months of the initial dose.
In addition, the initial dose of the vaccine continued to provide consistent protection against the virus, including against the Delta variant, the company said in a statement.
The latter news puts the vaccine in stark contrast to mRNA vaccines, which have shown waning immunity over time.
Mathai Mammen, J&J’s global head of R&D, told…
Source link
